A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer
Active, not recruitingCTIS2023-507172-44-00
F. Hoffmann-La Roche AGEstrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Start: 2021-09-10Target: 1482Updated: 2025-11-25